

Confirmed Speakers

KEYNOTE LECTURE

Molecular Recognition in Protein-Ligand Complexes



Prof. Gerhard KLEBE
(PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany)

INVITED LECTURES

SESSION 1: Method Development & Emerging Technologies

No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery



Dr Nino CAMPOBASSO
(GLAXOSMITHKLINE, Collegeville, United States)

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay



Dr Pär NORDLUND
(KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore)

Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery



Dr Joshua SALAFSKY
(BIODESY, South San Francisco, United States)

SESSION 2: Biophysics for Integral Membrane Proteins

Fluorine NMR Screening: Principles and Application to a Membrane Protein



Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology



Prof. Andreas PLÜCKTHUN
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

SESSION 3: Impact of Biophysics on Drug Discovery Projects

Biophysical Approaches for Hit Finding and Evaluation at Bayer



Dr Ursula EGNER
(BAYER, Berlin, Germany)

Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

Confirmed Speakers



Dr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

Some Examples of Biophysics Helping Drug Discovery



Prof. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design



Dr Vincent MIKOL
(SANOFI, Vitry-sur-Seine, France)

SESSION 4: The Use of Kinetics in Drug Discovery

CCR2 Antagonists: From Structure-Kinetics Relationships to in vivo Efficacy



Prof. Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics



Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure



Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

SESSION 5: Special Focus on Epigenetics

When to get Biophysical with Readers, Writers and Erasers



Dr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics



Dr Robert A. COPELAND
(EPIZYME, Cambridge, United States)

Interrogating the Bromodomain Family Through Chemical Biology

Confirmed Speakers



Dr Richard CUMMINGS
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

ORAL COMMUNICATIONS

Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)



Mr Alfonso ESPADA
(ELI LILLY, ALCOBENDAS, Spain)

A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics



Dr Amaury FERNANDEZ MONTALVAN
(BAYER, Biberach an der Riss, Germany)

Drug Discovery at the Single Molecule Level



Dr Anders GUNNARSSON
(ASTRAZENECA, Mölndal, Sweden)

First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design



Dr Krzysztof OKRASA
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment



Dr Anita WEGERT
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

Strategies to Target Protein-Protein Interactions



Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)